Milestone Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference

Rhea-AI Summary

Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical firm dedicated to cardiovascular medicine, announced management participation in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 29, 2022, at 1:30 p.m. ET in New York, NY. Investors can access a live webcast via Milestone's website, with an archived replay available for 90 days post-event. Milestone's lead product, etripamil, is in Phase 3 trials for treating paroxysmal supraventricular tachycardia and Phase 2 for atrial fibrillation with rapid ventricular rate.

MONTREAL and CHARLOTTE, N.C., Nov. 22, 2022 /PRNewswire/ -- Milestone Pharmaceuticals Inc. (Nasdaq: MIST), a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines, today announced that members of its management team will participate in a fireside chat at the Piper Sandler 34^th Annual Healthcare Conference on Tuesday, November 29, 2022 at 1:30 p.m. ET in New York, NY.

A live webcast of the fireside chat can be accessed in the News & Events section of Milestone's website at www.milestonepharma.com. An archived replay of the fireside chat will be available on the same website for approximately 90 days following the presentation.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc. (Nasdaq: MIST) is a biopharmaceutical company focused on the development and commercialization of innovative cardiovascular medicines. Milestone's lead product candidate etripamil is currently in a Phase 3 clinical-stage program for the treatment of paroxysmal supraventricular tachycardia (PSVT) and in a Phase 2 proof-of-concept trial for the treatment of patients with atrial fibrillation with rapid ventricular rate (AFib-RVR). Milestone Pharmaceuticals operates in Canada and the United States. For more information, visit www.milestonepharma.com and follow Milestone on Twitter at @MilestonePharma.

Contact

David Pitts
Argot Partners
212-600-1902
milestone@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/milestone-pharmaceuticals-to-present-at-the-piper-sandler-34th-annual-healthcare-conference-301684260.html

SOURCE Milestone Pharmaceuticals, Inc.

FAQ

When is Milestone Pharmaceuticals participating in the Piper Sandler 34th Annual Healthcare Conference?

Milestone Pharmaceuticals will participate on November 29, 2022, at 1:30 p.m. ET.

Where can I watch the Milestone Pharmaceuticals fireside chat?

The fireside chat can be accessed live on Milestone's website and will be available for replay for 90 days.

What is the focus of Milestone Pharmaceuticals' lead product, etripamil?

Etripamil is focused on treating paroxysmal supraventricular tachycardia and atrial fibrillation with rapid ventricular rate.

What is the ticker symbol for Milestone Pharmaceuticals?

The ticker symbol for Milestone Pharmaceuticals is MIST.